While federal drug pricing reforms have taken a back seat to the coronavirus pandemic during President Biden's first 100 days, interest in the topic remains strong among federal policymakers, state governments and voters.
In a Law360 article, health care partner Margaux Hall explores state legislative efforts in drug pricing and reporting and consider how the Biden administration and Congress might learn from states' experiences as the federal government crafts its own drug pricing policy for the next four years.
Stay Up To Date with Ropes & Gray
Ropes & Gray attorneys provide timely analysis on legal developments, court decisions and changes in legislation and regulations.
Stay in the loop with all things Ropes & Gray, and find out more about our people, culture, initiatives and everything that’s happening.
We regularly notify our clients and contacts of significant legal developments, news, webinars and teleconferences that affect their industries.